REGENXBIO RGNX Stock
REGENXBIO Price Chart
REGENXBIO RGNX Financial and Trading Overview
| REGENXBIO stock price | 10.72 USD |
| Previous Close | 11.28 USD |
| Open | 11.05 USD |
| Bid | 8.02 USD x 200 |
| Ask | 13.22 USD x 200 |
| Day's Range | 10.31 - 11.36 USD |
| 52 Week Range | 5.46 - 16.19 USD |
| Volume | 1.37M USD |
| Avg. Volume | 2.27M USD |
| Market Cap | 707.66M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.78 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.7 USD |
RGNX Valuation Measures
| Enterprise Value | 852.61M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.7002907 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0557847 |
| Price/Book (mrq) | 8.090566 |
| Enterprise Value/Revenue | 4.887 |
| Enterprise Value/EBITDA | -5.731 |
Trading Information
REGENXBIO Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 43.69% |
| S&P500 52-Week Change | 21.71% |
| 52 Week High | 16.19 USD |
| 52 Week Low | 5.46 USD |
| 50-Day Moving Average | 9.88 USD |
| 200-Day Moving Average | 10.53 USD |
RGNX Share Statistics
| Avg. Volume (3 month) | 2.27M USD |
| Avg. Daily Volume (10-Days) | 1.26M USD |
| Shares Outstanding | 66.01M |
| Float | 56.75M |
| Short Ratio | 2.94 |
| % Held by Insiders | 6.26% |
| % Held by Institutions | 66.07% |
| Shares Short | 8.63M |
| Short % of Float | 17.95% |
| Short % of Shares Outstanding | 16.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -112.57% |
| Operating Margin (ttm) | 27.09% |
| Gross Margin | -44.46% |
| EBITDA Margin | -85.26% |
Management Effectiveness
| Return on Assets (ttm) | -21.20% |
| Return on Equity (ttm) | -137.63% |
Income Statement
| Revenue (ttm) | 174.48M USD |
| Revenue Per Share (ttm) | 3.34 USD |
| Quarterly Revenue Growth (yoy) | 405.70% |
| Gross Profit (ttm) | -77586000 USD |
| EBITDA | -148776992 USD |
| Net Income Avi to Common (ttm) | -196432000 USD |
| Diluted EPS (ttm) | -3.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 105.52M USD |
| Total Cash Per Share (mrq) | 1.6 USD |
| Total Debt (mrq) | 250.46M USD |
| Total Debt/Equity (mrq) | 349 USD |
| Current Ratio (mrq) | 2.858 |
| Book Value Per Share (mrq) | 1.325 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -246674000 USD |
| Levered Free Cash Flow (ttm) | -184743504 USD |
Profile of REGENXBIO
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9804 Medical Center Drive |
| ZIP | 20850 |
| Phone | 240 552 8181 |
| Website | https://www.regenxbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 371 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Q&A For REGENXBIO Stock
What is a current RGNX stock price?
REGENXBIO RGNX stock price today per share is 10.72 USD.
How to purchase REGENXBIO stock?
You can buy RGNX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for REGENXBIO?
The stock symbol or ticker of REGENXBIO is RGNX.
Which industry does the REGENXBIO company belong to?
The REGENXBIO industry is Biotechnology.
How many shares does REGENXBIO have in circulation?
The max supply of REGENXBIO shares is 66.01M.
What is REGENXBIO Price to Earnings Ratio (PE Ratio)?
REGENXBIO PE Ratio is now.
What was REGENXBIO earnings per share over the trailing 12 months (TTM)?
REGENXBIO EPS is -3.78 USD over the trailing 12 months.
Which sector does the REGENXBIO company belong to?
The REGENXBIO sector is Healthcare.
REGENXBIO RGNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26690.62 USD — |
+1.3
|
7.21B USD — | 26478.01 USD — | 26712.62 USD — | — - | 7.21B USD — |
|
US Tech Composite Total Return
XCMP
US
|
32930.06 USD — |
+1.3
|
— — | 32667.75 USD — | 32957.2 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13105.24 USD — |
+1.29
|
— — | 13002.2 USD — | 13116.31 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3233.23 USD — |
+0.99
|
— — | 3216.03 USD — | 3236.96 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
4102.51 USD — |
+1.37
|
— — | 4067.35 USD — | 4113.35 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6781.84 USD — |
+1.84
|
— — | 6687.79 USD — | 6788.59 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.16 USD — |
+2.08
|
— — | 1273.79 USD — | 1294.2 USD — | — - | — — |
- {{ link.label }} {{link}}
